VANCOUVER, British Columbia, Canada--Biolux Research has announced that it has received a nonrepayable financial contribution from the National Research Council of Canada Industrial Research Assistance Program to help accelerate the development and commercialization of a new light treatment device for orthodontics.
The new product will be designed to accelerate tooth movement during orthodontic treatment, thus reducing treatment times while improving the patients' experience.
NRC-IRAP will contribute approximately CAD $205,000 during the next 18 months to support the research and prototyping of the device, to clinically test and validate the effectiveness of the technology, and to develop a high-quality, manufacturable product.
In addition to the contribution, NRC-IRAP will provide technical and business oriented advisory services.
NRC-IRAP works with small- and medium-sized Canadian firms, providing advice, as well as potential funding in developing their ideas. Financial assistance for this project is a direct result of the Government of Canada's Economic Action Plan outlined in the 2009 budget.
"This financial support from the Government of Canada through NRC-IRAP is very positive for Biolux, and enables us to pursue our research and development of our new orthodontics product in a timely manner, and ultimately accelerates the commercialization of the product into the market," stated Kevin Strange, president and CEO of Biolux.
"Orthodontics is a very large and important market for us, and is adjacent to the implant stability market for our initial product, the OsseoPulse Bone Regeneration System. There is a clear need for reducing treatment timelines for all orthodontic patients, which are typically 12 to 36 months, and we strongly believe that our technology will lead to a revolutionary approach to orthodontics," Strange added.
For more information, go to Biolux Research.
To read more about orthodontics, go to orthodontics.
To comment on this topic, go to PennWell Dental Community site.
